Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation – possible role of mutations in the YMDD motif prior totransplantation as a risk factor for reinfection
- 1 June 2001
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 34 (6), 895-902
- https://doi.org/10.1016/s0168-8278(01)00089-7
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Lamivudine (LAM) plus HBIg combination therapy compared to HBIg or notherapy in preventing hepatitis B (HBV) recurrence after livertransplantation (LT)Journal of Hepatology, 2000
- LAMIVUDINE FOR HEPATITIS B IN LIVER TRANSPLANTATIONTransplantation, 2000
- FULMINANT HEPATIC FAILURE RESULTING FROM LAMIVUDINE-RESISTANT HEPATITIS B VIRUS IN A RENAL TRANSPLANT RECIPIENTTransplantation, 1999
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Adefovir DipivoxilDrugs, 1999
- EFFICACY OF LAMIVUDINE IN CHRONIC HEPATITIS B PATIENTS WITH ACTIVE VIRAL REPLICATION AND DECOMPENSATED CIRRHOSIS UNDERGOING LIVER TRANSPLANTATION1Transplantation, 1996
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- SHOULD LIVER TRANSPLANTATION BE PERFORMED FOR PATIENTS WITH HEPATITIS B?Transplantation, 1994
- Hepatitis B virus reinfection after orthotopic liver transplantation: Serological and clinical implicationsJournal of Hepatology, 1992
- Liver transplantation in HBs antigen (HBsAg) carriers: Prevention of hepatitis B virus (HBV) recurrence by passive immunizationJournal of Hepatology, 1991